<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850991</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-15-11224</org_study_id>
    <nct_id>NCT02850991</nct_id>
  </id_info>
  <brief_title>Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Phase III Trial Evaluating High-dose Versus Standard-dose Radiation With Concurrent Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Definitive chemoradiation is the standard treatment for locally advanced esophageal cancer.&#xD;
      NCCN (National Comprehensive Cancer Network) recommends radiation dose of 50-50.4 Gy as the&#xD;
      definitive radiation dose for esophageal cancer with definitive chemo-radiation. However, as&#xD;
      many studies in China showed that the most common recurrence site after definitive&#xD;
      chemo-radiation was within the radiation region. But there have not been large randomized&#xD;
      clinical trials to investigate the optimal radiation dose with concurrent chemotherapy for&#xD;
      esophageal cancer in China. The purpose of this clinical trial is to investigate the optimal&#xD;
      radiation dose for thoracic esophageal squamous cell cancer with definitive concurrent&#xD;
      chemoradiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if high-dose radiation with concurrent chemotherapy increases overall&#xD;
      survival for thoracic esophageal squamous cell carcinoma&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate if high-dose radiation with concurrent chemotherapy increased progression-free&#xD;
      survival for thoracic esophageal squamous cell carcinoma II.To evaluate if high-dose&#xD;
      radiation with concurrent chemotherapy increased local control for thoracic esophageal&#xD;
      squamous cell carcinoma&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients are randomized to one of the two treatment arms&#xD;
&#xD;
      ARM 1:Patients receive high-dose radiation with concurrent chemotherapy.High-dose RT:59.4 Gy&#xD;
      in 33 fractions, 1.8 Gy per fraction, 5days/week.concurrent chemotherapy: Paclitaxel 50mg/m2&#xD;
      D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks. After that, patients receive&#xD;
      consolidative platinum-based 3-week chemotherapy for 2 cycles.&#xD;
&#xD;
      ARM 2:Patients receive standard-dose radiation with concurrent chemotherapy.Standard-dose&#xD;
      RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week . Concurrent chemotherapy:&#xD;
      Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks. After&#xD;
      that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3-4 months for 2 years,&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>High dose radiation plus chemotherapy of paclitaxel and carboplatin vs standard dose radiation plus chemotherapy of paclitaxel and carboplatin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>local control rate, recurrence pattern</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.&#xD;
After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.&#xD;
After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High-dose</intervention_name>
    <description>Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms</description>
    <arm_group_label>High-dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard-dose</intervention_name>
    <description>Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms</description>
    <arm_group_label>Standard-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form&#xD;
&#xD;
          2. Age: 18-75 years&#xD;
&#xD;
          3. Histological or cytologic diagnosis of esophageal squamous cell carcinoma within one&#xD;
             month. Clinical stage T1-4 N0-1 M0-1a (AJCC 6th edition）. Supraclavicular lymphatic&#xD;
             metastasis or abdominal lymph node metastasis for mid-thoracic also can be included&#xD;
&#xD;
          4. Karnofsky performance status scores: ≥70&#xD;
&#xD;
          5. Without any prior anticancer therapy&#xD;
&#xD;
          6. BMI≥18kg/m2 or weight loss ≤5% within 3 months&#xD;
&#xD;
          7. Adequate marrow function (within 7 days): White blood cell ≥ 3×109/L,Neutrophils (ANC)&#xD;
             ≥1.5×109/L, Platelet count ≥100×109/L, Hemoglobin ≥90g/L. Normal hepatic and renal&#xD;
             function (within 14 days): Total bilirubin &lt;1.5 x upper limit of normal (ULN), Alanine&#xD;
             aminopeptidase and Aspartase aminotransferase ≤ 2.5 x ULN, creatinine ≤ 1.5xULN&#xD;
&#xD;
          8. Normal cardiac and pulmonary function: Forced expiratory volume at one second (FEV1)&#xD;
             ≥1.0 L or FEV1/FVC ≥ 50% pre FEV1; No myocardial infarction within 1 year; no&#xD;
             symptomatic heart disease, including myocardial ischemia, congestive heart failure or&#xD;
             uncontrolled arrhythmias, roughly normal electrocardiogram; LVEF ≥ 50%，or can receive&#xD;
             chemoradiotherapy assessed by cardiologists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other or mixed pathological type&#xD;
&#xD;
          2. The second primary tumor of esophageal cancer located outside the radiation area&#xD;
&#xD;
          3. Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula&#xD;
&#xD;
          4. Mid-thoracic esophageal cancer with supraclavicular lymphatic metastasis and abdominal&#xD;
             lymph node metastasis; other metastasis&#xD;
&#xD;
          5. Within 2cm of the gastroesophageal junction&#xD;
&#xD;
          6. Prior chemotherapy, prior thoracic radiation, surgical resection or target therapy of&#xD;
             the primary tumor&#xD;
&#xD;
          7. Significant medical or psychiatric illnesses that in the physician's judgment&#xD;
             (uncontrolled coronary heart disease, cardiomyopathy and/or heart failure requiring&#xD;
             hospitalization. Uncontrolled hypertension or history of myocardial infarction within&#xD;
             one year. Uncontrolled diabetes mellitus. Acute bacterial or fungal infection&#xD;
             requiring intravenous antibiotics. Acute exacerbation of chronic obstructive pulmonary&#xD;
             disease (COPD) or other pulmonary disease requiring hospitalization influencing tumor&#xD;
             treatment&#xD;
&#xD;
          8. Refused to sign informed consent form&#xD;
&#xD;
          9. Concurrent pregnancy or lactation&#xD;
&#xD;
         10. History of a second malignancy other than nonmelanoma skin cancer, and cervical cancer&#xD;
             in situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anhui Shi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Anhui Shi, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer, radiation, chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

